文献速递浆细胞疾病造血干细胞移植与细胞治疗

B细胞成熟抗原靶向CAR T细胞治疗后第100天后以呼吸道感染为主

Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy.
PubMed 文献 · Blood Adv · 2023-01-01

该研究评估了99例接受B细胞成熟抗原(BCMA)靶向CAR T细胞治疗的复发/难治性多发性骨髓瘤成人患者,随访至第365天。37%患者发生64次感染事件,呼吸道感染在晚期(第101-365天)占比升至77%,低丙种球蛋白血症和早期呼吸道病毒感染是晚期呼吸道感染的独立危险因素。

要点

  • 37%患者在第一年发生感染,晚期呼吸道感染占晚期事件的77%。
  • 低丙种球蛋白血症(HR 6.06)和早期呼吸道病毒感染(HR 2.95)是晚期呼吸道感染独立危险因素。
  • 呼吸道感染在BCMA CAR T细胞治疗后第100天后占主导地位。

核心结论

  • BCMA CAR T细胞治疗后呼吸道感染占主导,尤其在第100天后;低丙种球蛋白血症和早期呼吸道感染是晚期呼吸道感染的危险因素,可能用于指导靶向预防策略。

研究设计与样本

  • 研究纳入2016年11月至2022年5月期间接受首次BCMA靶向CAR T细胞治疗(商业和研究中自体BCMA CAR T细胞产品,按推荐2期剂量)的99例复发/难治性多发性骨髓瘤成人患者。
  • 感染记录至第365天,包括有微生物学诊断的症状或需抗菌药物治疗的症状性部位特异性感染;采用无感染死亡和接受额外抗肿瘤治疗作为竞争风险计算首次呼吸道感染的一年累积发病率函数。
  • 二次分析使用单变量和多变量Cox回归模型评估晚期呼吸道感染的危险因素。

主要发现

  • 37例患者(37%)在BCMA CAR T细胞治疗后第一年发生64次感染事件,其中早期感染事件42次(第0-100天),晚期感染事件22次(第101-365天)。
  • 呼吸道感染是最常见的部位特异性感染,晚期呼吸道感染相对比例增加(早期事件的31% vs 晚期事件的77%)。
  • 多变量分析显示,低丙种球蛋白血症(HR 6.06;P = .044)和早期呼吸道病毒感染诊断(HR 2.95;P = .048)是晚期呼吸道感染的独立危险因素。

关键数值与推荐

  • 一年累积发病率函数基于首次呼吸道感染时间计算,以无感染死亡和接受额外抗肿瘤治疗为竞争风险。
  • 低丙种球蛋白血症的HR为6.06(P = .044),早期呼吸道病毒感染的HR为2.95(P = .048),均为晚期呼吸道感染的独立危险因素。

临床怎么用

  • 低丙种球蛋白血症和早期呼吸道感染诊断是晚期呼吸道感染的危险因素,可能用于指导靶向预防策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infections are an important complication after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy and risks may differ between the early and late periods. We evaluated infections in 99 adults who received a first BCMA-directed CAR T-cell therapy (commercial and investigational autologous BCMA CAR T-cell products at the recommended phase 2 dose) for relapsed/refractory multiple myeloma between November 2016 and May 2022. Infections were recorded until day 365, if patients experienced symptoms with a microbiologic diagnosis, or for symptomatic site-specific infections treated with antimicrobials. One-year cumulative incidence functions were calculated based on time to first respiratory infection using dates of infection-free death and receipt of additional antineoplastic therapies as competing risks. Secondary analysis evaluated risk factors for late respiratory infections using univariate and multivariable Cox regression models. Thirty-seven patients (37%) experienced 64 infectious events over the first year after BCMA-directed CAR T-cell therapy, with 42 early infectious events (days, 0-100), and 22 late infectious events (days, 101-365). Respiratory infections were the most common site-specific infection and the relative proportion of respiratory infections increased in the late period (31% of early events vs 77% of late events). On multivariable analysis, hypogammaglobulinemia (hazard ratio [HR], 6.06; P = .044) and diagnosis of an early respiratory viral infection (HR, 2.95; P = .048) were independent risk factors for late respiratory infection. Respiratory infections predominate after BCMA CAR T-cell therapy, particularly after day 100. Hypogammaglobulinemia and diagnosis of an early respiratory infection are risk factors for late respiratory infections that may be used to guide targeted preventive strategies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Little JS, Tandon M, Hong JS, et al. Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy. Blood Adv. 2023. PMID: 37486599. doi:10.1182/bloodadvances.2023010524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。